Intellia Competitors
| NTLA Stock | USD 13.15 0.75 5.40% |
Intellia Therapeutics vs Veru Correlation
Very weak diversification
The correlation between Intellia Therapeutics and VERU is 0.56 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Intellia Therapeutics and VERU in the same portfolio, assuming nothing else is changed.
Moving against Intellia Stock
As of February 1, 2026, Return On Tangible Assets is expected to decline to -0.41. In addition to that, Return On Capital Employed is expected to decline to -0.6. At present, Intellia Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 665.5 M, whereas Total Assets are forecasted to decline to about 743.3 M.Intellia Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Intellia Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Intellia and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Intellia Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Intellia Stock performing well and Intellia Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Intellia Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| STRR | 1.83 | (0.10) | 0.00 | (0.09) | 0.00 | 3.21 | 12.75 | |||
| NOTV | 4.51 | (1.38) | 0.00 | (0.50) | 0.00 | 7.41 | 39.39 | |||
| YI | 4.79 | 1.01 | 0.22 | 11.22 | 3.91 | 15.20 | 47.07 | |||
| PRPO | 2.82 | 0.32 | 0.09 | (1.25) | 2.89 | 8.79 | 21.67 | |||
| NMTC | 3.62 | 0.11 | 0.04 | 0.08 | 3.81 | 9.59 | 23.46 | |||
| RMTI | 3.75 | 0.06 | 0.00 | (0.14) | 4.01 | 6.38 | 40.19 | |||
| ECOR | 3.91 | 0.51 | 0.14 | 0.26 | 3.69 | 10.17 | 31.20 | |||
| BTAI | 4.02 | (0.50) | 0.00 | (0.19) | 0.00 | 8.90 | 22.33 | |||
| CCEL | 2.19 | (0.46) | 0.00 | (1.46) | 0.00 | 4.71 | 16.21 | |||
| VERU | 3.24 | (0.48) | 0.00 | 2.70 | 0.00 | 6.07 | 17.23 |
Cross Equities Net Income Analysis
Compare Intellia Therapeutics and related stocks such as Star Equity Holdings, Inotiv Inc, and 111 Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STRR | (13.5 M) | (3.3 M) | (4.9 M) | 264 K | 2.5 M | 21.6 M | 14.3 M | (35.7 M) | 736 K | (4.6 M) | (6.5 M) | (3 M) | (5.3 M) | 2.2 M | (10.4 M) | (12 M) | (11.4 M) |
| NOTV | 700 K | (6.4 M) | 773 K | (1.1 M) | 1.1 M | (3.2 M) | 884 K | (194 K) | (790 K) | (4.7 M) | 10.9 M | (337.3 M) | (105.1 M) | (108.4 M) | (68.6 M) | (61.8 M) | (58.7 M) |
| YI | (362.7 M) | (362.7 M) | (362.7 M) | (362.7 M) | (362.7 M) | (362.7 M) | (362.7 M) | (248.6 M) | (380.1 M) | (501.8 M) | (456.5 M) | (669.8 M) | (416.9 M) | (392.7 M) | (64.7 M) | (74.5 M) | (78.2 M) |
| PRPO | (9.8 M) | (9.8 M) | (8.3 M) | (16 M) | (13.9 M) | (33 M) | (7.6 M) | (20.7 M) | (15.7 M) | (13.2 M) | (10.6 M) | (8.6 M) | (12.2 M) | (5.9 M) | (4.3 M) | (4.9 M) | (5.2 M) |
| NMTC | (6 K) | (14 K) | (14 K) | (30.6 K) | (36.2 K) | (62.9 K) | (47.8 K) | (6.8 M) | (6.8 M) | (13.6 M) | (9.9 M) | (10 M) | (11.9 M) | (12.3 M) | (3.6 M) | (3.2 M) | (3.4 M) |
| RMTI | (1.9 M) | (21.4 M) | (54 M) | (48.8 M) | (21.3 M) | (14.4 M) | (19.8 M) | (25.9 M) | (32.1 M) | (34.1 M) | (30.9 M) | (32.7 M) | (18.7 M) | (8.4 M) | (480 K) | (432 K) | (453.6 K) |
| ECOR | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (35.8 M) | (55.8 M) | (45.1 M) | (23.5 M) | (17.2 M) | (22.2 M) | (18.8 M) | (11.9 M) | (13.7 M) | (14.4 M) |
| BTAI | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (2.1 M) | (4.5 M) | (19.3 M) | (32.3 M) | (82 M) | (106.6 M) | (165.8 M) | (179.1 M) | (59.6 M) | (53.6 M) | (56.3 M) |
| CCEL | 600 K | (6.3 M) | 27.4 K | 553.6 K | 8.1 M | (1.3 M) | 2.3 M | (854.8 K) | 2.3 M | 3.6 M | 2.1 M | 2.8 M | (9.5 M) | 402.1 K | 402.1 K | 462.4 K | 485.5 K |
| VERU | 300 K | 15.3 M | 14.3 M | 2.4 M | 4.3 M | 344.7 K | (6.6 M) | (23.9 M) | (12 M) | (19 M) | 7.4 M | (83.8 M) | (93.2 M) | (37.8 M) | (22.7 M) | (20.5 M) | (19.4 M) |
Intellia Therapeutics and related stocks such as Star Equity Holdings, Inotiv Inc, and 111 Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Intellia Therapeutics financial statement analysis. It represents the amount of money remaining after all of Intellia Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Intellia Therapeutics Competitive Analysis
The better you understand Intellia Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Intellia Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Intellia Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Intellia Therapeutics Competition Performance Charts
Five steps to successful analysis of Intellia Therapeutics Competition
Intellia Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Intellia Therapeutics in relation to its competition. Intellia Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Intellia Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Intellia Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Intellia Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Intellia Therapeutics position
In addition to having Intellia Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Stores Thematic Idea Now
Stores
Companies providing different types of retail and wholesale services. The Stores theme has 18 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Stores Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Intellia Therapeutics Correlation with its peers. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. Anticipated expansion of Intellia directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Intellia Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.25) | Revenue Per Share | Quarterly Revenue Growth 0.513 | Return On Assets | Return On Equity |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Intellia Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Intellia Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Intellia Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.